Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma 2Rhabdoid Tumor 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasms 1Medulloblastoma 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Glioma 1Ependymoma 1Cytomegalovirus Infections 1Choroid Plexus Carcinoma 1Burkitt Lymphoma 1Brain Neoplasms 1

Interventions

dolutegravir 1Stem Cell Transplantation 1Specimen Handling 1Ritonavir 1Nucleosides 1Darunavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Cytomegalovirus Infections × Stem Cell Transplantation × Clear all
NCT05589844 2023-04-27

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Roswell Park Cancer Institute

Phase 1 Withdrawn

Cytomegalovirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡